New NASH Flyer 02/01/2017 03:15

RenaSci have recently evaluated the choline deficient (CD) and methionine and choline deficient (MCD) diet mouse models of non-alcoholic steatohepatitis (NASH). 

Non-alcoholic fatty liver disease (NAFLD) is the excessive accumulation of lipid in the liver. Simple hepatic steatosis is a relatively benign condition and usually reversible. However, if lipids continue to accumulate and the liver becomes inflamed it can progress into non-alcoholic steatohepatitis (NASH). NASH is characterised by lobular inflammation and hepatocellular ballooning and is often associated with fibrosis. Risk factors for NASH include obesity and diabetes. 

The MCD diet has been used for many years to induce NASH. It produces the histological features associated with NASH but marked weight-loss and reductions in plasma glucose and insulin. The CD diet was assessed as there is some evidence that it may produce less weight-loss than the MCD diet. The PPARγ agonist, pioglitazone, was employed as a standard as it has been shown to be of benefit in the treatment of NASH in man.

Mice were maintained on the different diets for 6 weeks. Plasma and liver samples were then taken for analysis. Both diets increased NAS (non-alcoholic fatty liver disease (NAFLD) activity scores) and fibrosis (collagen deposition scores), liver lipids and plasma levels of liver enzymes compared to control mice on normal diet consistent with the development of NASH. These responses were, in general, inhibited by pioglitazone.

The CD diet had a clear advantage over the MCD diet as it produced much less weight-loss.

These results demonstrate that mice maintained on a CD diet can be used as a simple model to identify compounds with potential for the treatment of NASH.

Please click here to see our new flyer on the CD and MCD diet mouse models of NASH.